Mizuho lowered the firm’s price target on Boston Scientific (BSX) to $90 from $115 and keeps an Outperform rating on the shares. The firm lowered estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $87 from $94 at Citi
- Boston Scientific price target lowered to $80 from $96 at Evercore ISI
- Boston Scientific Investors File Lawsuit Over Alleged Misleading Statements About Electrophysiology Business Growth
- AI Models Turn More Positive on Boston Scientific, But Weak Technicals Temper Enthusiasm
- FTC issued Second Request to Penumbra, Boston Scientific over merger review